Peptonic Medical: Request for extension of company reconstruction and update on the reconstruction process

Peptonic Medical AB (publ) (“Peptonic” or the “Company”) has today submitted a request to the Uppsala District Court to extend the ongoing company reconstruction by three months, through 13 September 2025. The request is supported by the Company’s appointed reconstruction administrator. The reason for the extension is that the Company, together with the administrator, is in the process of finalizing a reconstruction plan. The intention is to submit this plan to the court for formal proceedings within the extended period, subject to the court’s approval of the extension.

Request for Extension of the Company Reconstruction                                                                      
On 8 June 2025, the Company submitted a formal request to the Uppsala District Court to extend the ongoing company reconstruction by three months. This follows the previously communicated timeline, where the reconstruction was expected to be completed within three to six months from the application date.

The aim of the extension is to finalize the reconstruction plan and submit a request for formal plan proceedings under the Swedish Company Reconstruction Act during this three-month period.

Revised Forecast                                                                                                                               
The previously communicated forecast from March 2025 has been revised due to delays in manufacturing, deliveries, and marketing activities that occurred as a result of the reconstruction process, as well as market disruptions following the U.S. administration's implementation of tariffs against other markets. These delays are primarily attributable to the fact that the new share issue ongoing at the time of the reconstruction filing could only be completed and registered on 28 April 2025. The resulting liquidity shortage during the initial phase of the reconstruction led to approximately a three-month delay in the Company’s U.S. expansion efforts. In addition to operational delays, the summer months are expected to contribute to a slower market uptake than previously projected. The revised forecast takes these factors into account and is based on conservative assumptions. It reflects a worst-case scenario and also considers ongoing uncertainties in the U.S. market, including tariffs, as well as potential disruptions during the continued reconstruction process.

According to the revised forecast, the worst-case scenario, the Company, including subsidiaries (the “Group”) is expected to reach break-even in November 2025. Despite the conservative outlook, the Company believes that the planned reconstruction measures are sufficient to ensure liquidity through April 2026, even assuming sales remain at levels consistent with recent months.

Forward-looking projections further indicate that the Group expects to reach approximately SEK 20 million in revenue during 2025. Group revenue is expected to decrease by approximately  - 7 MSEK compared with 2024. Group results are expected to amount to approximately -12 MSEK for EBITDA and  -18 MSEK for EBIT.

U.S. Market Initiatives                                                                                                                                  
The U.S. remains a central part of the Company’s growth strategy. Due to recent developments, the Company has conducted an evaluation of its distribution structures and tariff-related matters. The Company maintains its ambition to generate a significant portion of group revenue from the U.S. market.

Home Market: The Nordics                                                                                                                  
In parallel with U.S. operations, the Company has intensified its activities in the Nordic home market. The pace of investment has increased, and the Company has initiated collaborations with new agencies with extensive e-commerce expertise, including advertising via Meta and Google Ads. These efforts aim to rapidly increase reach, conversion rates, and digital sales. The impact of these measures is expected to materialize in the second half of 2025 and is an integral part of the commercial plan.

Capital Raising and Share Issues                                                                                                                        
As part of the restructuring measures, the Company has entered into agreements regarding debt-to-equity conversions, whereby Rosland Nordic AB and Fenja Capital Partners A/S intend to convert their receivables into shares in the Company. These share issues are conditional upon the approval and legal force of the restructuring plan by relevant parties and the court. In parallel, the Company is exploring the potential for additional debt-to-equity conversions with other creditors.

In addition, the principal shareholder, Maida Vale Capital AB, has committed to investing SEK 10 million in a directed share issue. This commitment is conditional upon the reconstruction plan being approved and coming into legal force, and the Swedish Securities Council granting an exemption from the mandatory bid obligation. Since the Company is considered to operate a security-sensitive business under the Foreign Direct Investment Screening Act (2023:560), Maida Vale Capital AB has also initiated the filing process with the inspectorate of strategic products.

Next steps                                                                                                                                             
The Company intends to finalize the reconstruction plan and request court approval proceedings within the upcoming three-month period.

The Board of Directors considers that the reconstruction measures, including the capital injection, are both necessary and sufficient to resolve the Company’s financial difficulties and to safeguard its long-term viability.

This disclosure contains information that PEPTONIC Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on June 8, 2025, 21.50 CET.

For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB                                                                                                      
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07

About Peptonic Medical AB                                                                                                        
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.

The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.

Läs mer på Cision